Adenosine Analogs as Possible Differentiation-Inducing Agents Against Acute Myeloid Leukemia

References

• Collins S. J., Bodner A., Ting R., Gallo R. C. Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by compounds which induce differentiation of murine leukemia cells. Int. J. Cancer 1980; 25: 213–218
   PubMed Web of Science ®Google Scholar
• Bodner A. J., Ting R., And C., Gallo R. C. Induction of differentiation of human promyelocytic leukemia cells (HL-60) by nucleosides and methotrexate. J. Natl. Cancer Inst. 1981; 67: 1025–1030
   PubMed Web of Science ®Google Scholar
• Ishiguro K., Schwartz E., And L., Sartorelli A. C. Characterization of the metabolic forms of 6-thioguanine responsible for cytotoxicity and induction of differentiation of HI-60 acute promyelocytic leukemia cells. J. Cell. Physiol. 1984; 121: 383–390
   PubMed Web of Science ®Google Scholar
• Rowley P. T., Ohlsson-Wilhelm B. M., Farely B., And A., Labella S. Inducers of erythroid differentiation of K562 human leukemia cells. Exp. Hematol. 1981; 9: 32–37
   PubMed Web of Science ®Google Scholar
• Castaigne S., Daniel M. T., Tilly H., Herait P., Degos L. Does treatment with & a-C in low dosage cause differentiation of leukemic cells?. Blood 1983; 62: 85–91
   PubMed Web of Science ®Google Scholar
• Hellstrom R, Robert K. H., Soppi E., Ost E., Putkonen P., And O., Gahrton G. Effects of retinoic acid, 1, 25-dihydroxyvitamin D., cytosine arabinoside and α-interferon on bone marrow cells from patients with myelo-dysplastic syndromes. Leuk. Res 1989; 13: 1113–1121
   PubMed Web of Science ®Google Scholar
• Honma Y., Ikuta T., Kasukabe T., Hozumi M., Itoh T., Ogura H. Inhibition of proliferation and induction of differentiation of human myeloid leukemia cells by novel nucleoside analogs. Anticancer Res. 1988; 8: 695–699
   PubMed Web of Science ®Google Scholar
• Makishima M., Honma Y., Hozumi M., Sampi K., Hatton M., Ishikawa I., Ogura H., Kawahara N., Kanaiwa T., Motoyoshi K. Induction of differentiation of human myeloid leukemia HL-60 cells by novel pyrimidine nucleo-side analogs. Biochim. Biophys. Acta 1991; 1094: 1–7
   PubMed Web of Science ®Google Scholar
• Makishima M., Honma Y., Hozumi M., Sampi K., Hatton M., Ishikawa I., Ogura H., Motoyoshi K. Effects of novel uracil analogs on proliferation and differentiation of human myeloid leukemia cells. Exp. Hematol. 1992; 20: 879–885
   PubMed Web of Science ®Google Scholar
• Kanatani Y., Makishima M., Ishikawa I., Ogasawara Y., Kawahara N., Motoyoshi K., Nagata N., Honma Y. A novel uracil analog, 6-chloro-5–(2-propenyl)uracil, preferentially enhances growth inhibition and differentiation of myeloid leukemia cells induced by 1α.,25-dihydroxy-vitamin D3. Exp. Hematol. 1998; 26: 198–206
   PubMed Web of Science ®Google Scholar
• Gilbert E. R., Anderson F., Cohen B., Pollana B., Mewissen H. J. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2: 1067–1068
   PubMed Web of Science ®Google Scholar
• Mitchell B., And S., Kelley W. N. Punnogenic immunodeficiency diseases: clinical features and molecular mechanisms. Ann. Intern. Med. 1980; 92: 826–832
   PubMed Web of Science ®Google Scholar
• Lepage G. A., Khalig A., Gottlieb J. A. Studies of 9–β-D-arabinofuranosyladenine in man. Drug Metab. Dispos. 1973; 1: 756–759
   PubMed Web of Science ®Google Scholar
• Montgomery J. A. Studies on the biologic activity of purine and pyrimidine analogs. Med. Res. Rev. 1982; 2: 271–308
   PubMed Web of Science ®Google Scholar
• Brockman R. W., Schabel F., And M. J., Montgomery J. A. Biologic activity of 9–β-D-arabinofuranosyl-2-fluo-roadenine, a metabolically stable analog of 9–β-D-arabinofuranosyladenine. Biochem. Pharmacol. 1977; 26: 2193–2196
   PubMed Web of Science ®Google Scholar
• Keating M. J., Keating M.J., Plunkett W. Clinical trials of the purine analogs in chronic lymphocytic leukemia. Nucleoside Analogs in Cancer Therapy, B. D. Cheson, 1997; 201–226, New York Marcel Dekker.
   Google Scholar
• Saven A., Piro L. D., Keating M.J., Plunkett W. Treatment of hairly cell leukemia with nucleoside analogs. Nucleoside Analogs in Cancer Therapy, B. D. Cheson. Marcel Dekker., New York 1997; 227–246
   Google Scholar
• Hiddemann W., Pott-Hoeck C., Keating M.J., Plunkett W. Clinical trials with nucleoside analogs in lymphomas. In. Nucleoside Analogs in Cancer Therapy, B. D. Cheson. Marcel Dekker., New York 1997; 247–288
   Google Scholar
• Niitsu N., Umeda M., Honma Y. Induction of differentiation of human myeloid leukemia cells by 2′-deoxycoformycin in combination with 2′-deoxyadenosine. Biochem. Biophys. Res. Commun. 1997; 238: 100–106
   PubMed Web of Science ®Google Scholar
• Matsumoto M., Tihan T., Cory J. C. Effect of ribonucleotide-reductase inhibitors on the growth of human colon-carcinoma HT29 cells in culture. Cancer Chemother Pharmacol. 1990; 26: 323–329
   PubMed Web of Science ®Google Scholar
• Hershfield M. S. Apparent suicide inactivation of human lymphoblast S-adenosyl homocysteine hydrolase by 2′-deoxyadenosine and adenine arabinoside. J. Biol. Chem. 1979; 254: 22–25
   PubMed Web of Science ®Google Scholar
• Yaginuma S., Muto N., Tsujino M., Sudate Y., Hayashi M., Otani M. Studies on neplanocin A. New antitu-mor antibiotic I. Producing organism, isolation and characterization. J. Antibiot. 1981; 34: 359–366
   PubMed Web of Science ®Google Scholar
• Glazer R., And I., Knode M. C. Neplanocin A. A cyclopentenyl analog of adenosine with specificity for inhibiting RNA methylation. J. Biol. Chem. 1984; 259: 12964–12969
   PubMed Web of Science ®Google Scholar
• Zimmerman T. P., Schmitges C. J., Wolberg G., Deeprose R. D., Duncan G. S., Cuatrecasas P., Elion G. B. Modulation of cyclic AMP metabolism by S-adenosylho-mocysteine and S-3-deazaadenosylhomocysteine in mouse lymphocytes. Proc. Natl. Acad. Sci. USA 1980; 77: 5639–5643
   PubMed Web of Science ®Google Scholar
• Liu X., Kim C. N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 1996; 86: 147–157
   PubMed Web of Science ®Google Scholar
• Li P., Nijhawan D., Budihardjo I., Srinivasula S. M., Ahmadt M., Alnemri E., And S., Wang X. Cytochrome C and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479–439
   PubMed Web of Science ®Google Scholar
• Dion H. W., Woo P., And W. K., Ryder A. Isolation and properties of a vidarabine deaminase inhibitor. co-vidarabin. Ann. N. Y. Acad. Sci. 1977; 284: 21–29
   Web of Science ®Google Scholar
• Smyth J. F., Paine R. M., Jackman A. L., Harrap K. R., Chassin M. M., Adamson R. H., Johns D. G. The clinical pharmacoiogy of the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Chemother, Phannacol. 1980; 5: 93–101
   PubMed Web of Science ®Google Scholar
• Kraut E. H., Grever M., And R., Bouroncle B. A. Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 1994; 84: 4061–4063
   PubMed Web of Science ®Google Scholar
• Yamaguchi K., Yul L. S., Oda T., Maeda T., Ishii Y., Fujita M., Kagiyama K., Nagai S., Suzuki K., Takatsuki K. Clinical consequences of 2′-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia. Leuk. Res. 1986; 10: 989–993
   PubMed Web of Science ®Google Scholar
• Blick M., Lepe-Zuniga J. L., Doig R., Quesada J. R. Durable complete remissions after 2′-deoxycofor-mycin treatment in patients with hairy cell leukemia resistant to interferon alpha. Am. J. Hematol. 1990; 33: 205–209
   PubMed Web of Science ®Google Scholar
• Foon K. A., Rai K., And R., Gale R. P. Chronic lymphocytic leukemia: New insights into biology and therapy. Ann. Intern. Med. 1990; 113: 525–539
   PubMed Web of Science ®Google Scholar
• Cassileth P. A., Cheuvart B., Speirs A. S.D., Harrington D. P., Cummings F. J., Neiman R. S., Bennett J., And M., O'Connell M. J. Pentostatin induces durable remissions in hairy cell leukemia. J. Clin. Oncol. 1991; 9: 243–246
   PubMed Web of Science ®Google Scholar
• Kefford R., And F., Fox R. M. Purine deoxyribonucle-oside toxicity in non-dividing human lymphoid cells. Cancer Rex 1982; 42: 326–330
   Google Scholar
• Earle M., And F., Glazer R. I. 2′-Deoxycoformycin toxicity in murine spleen lymphocytes. Mol. Phamacol. 1983; 23: 165–170
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Lakow E., Kamatani N. Possible metabolic basis for the different immunode-ficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc. Natl. Acad. Sci. USA 1982; 79: 3848–3852
   PubMed Web of Science ®Google Scholar
• Fox R. M., Kefford. R. F., Tripp E., And H., Taylor I. W. G1-phase arrest of cultured human leukemic T-cells induced by deoxyadenosine. Cancer Res. 1981; 41: 5141–5150
   PubMed Web of Science ®Google Scholar
• Fox R. M., Tripp E., And H., Taylor I. W. Analytical DNA flow cytometric analysis of deoxyadenosine toxicity in cultured human leukemic lymphoblasts. Mol. Pharmacol. 1984; 26: 388–394
   PubMed Web of Science ®Google Scholar
• Daddona P. Human adenosine-deaminase properties and turnover in cultured T and B lymphoblast. J. Biol. Chem. 1981; 256: 12496–12501
   PubMed Web of Science ®Google Scholar
• Carson D. A., Kaye J., Matsumoto S., Seegmiller J., And E., Thompson L. Biochemical basis for the enhanced toxicity of deoxyribonucleotides toward malignant human T-cell lines. Proc. Natl. Acad. Sci. USA 1979; 76: 2436–2433
   Google Scholar
• Miller R. L., Admaczyk D. L., Miller W. H., Koszalka G. W., Rideout J. L., Beacham L. M., Chao E. Y., Haggerty J. J., Krenitsky T., And A., Elion G. B. Adenosine kinase from rabbit liver. II. Substrate and inhibitor specificity. J. Biol. Chem. 1979; 254: 2346–2352
   PubMed Web of Science ®Google Scholar
• Pilz R. B., Huvar I., Scheele J. S., Van Den Berghe G., Boss G. R. A decrease in the intracellular guanosine 5′-triphosphate concentration is necessary for granulocytic differentiation of HL-60 cells, but growth cessation and differentiation are not associated with a change in the activation state of ras, the transforming principle of HL-60 cells. Cell Growth Diffser 1997; 8: 53–59
   PubMedGoogle Scholar
• Honma Y., Kasukabe T., Hozumi M. Decrease in phospholipid methylation during differentiation of cultured mouse myeloid leukemia cells. Biochim. Biophys. Acta 1981; 664: 441–444
   PubMed Web of Science ®Google Scholar
• Mizutani Y., Masuoka S., Imoto M., Kamada M., Umezawa K. Induction of erythroid differentiation in leukaemic K562 cells by an S-adenosylhomocysteine hydrolase inhibitor aristeromycin. Biochem. Biophys. Res. Commun. 1995; 207: 69–74
   PubMed Web of Science ®Google Scholar
• Tsujino M., Yaginuma S., Fujii T., Hayano K., Matsuda T., Watanabe T., Abe J. Neplanocins new antitumor agents biological activity. Cur, Chemo the, Infect. Dis. 1981; 3: 1559–1561
   Google Scholar
• Niitsu N., Yamamoto-Yamaguchi Y., Kanatani Y., Shuto S., Matsuda A., Umeda M., Honma Y. Neplano-cin A, a potent inhibitor of S-adenosylhomocysteine hydro-lase, potentiates granulocytic differentiation of acute promyelocytic leukemia cells induced by all-trans retinoic acid. Exp. Hematol. 1997; 25: 1296–1303
   PubMed Web of Science ®Google Scholar
• North T., And H., Cohen S. S. Arabinosylnucleoside and nucleotides in viral chemotherapy. Pharmacol. The. 1979; 4: 81–108
   Google Scholar
• Brink J., And J., Lepage G. A. Metabolic effects of 9–β-D-arabinosyl-purines in ascites tumor cells. Cancer Rex 1964; 24: 312–318
   PubMed Web of Science ®Google Scholar
• Liliemark J., Juliusson G., Keating M.J., Plunkett W. Pharmacokinetics of purine nucleoside analogs. In. Nucleoside Analogs in Cancer Therapy, B. D. Cheson. Marel Dekker., New York 1997; 73–93
   Google Scholar
• Tallman M., And S., Hakimian D. Purine nucleoside analogs: Emerging roles in indolent Iymphoproliferative disorders. Blood 1995; 86: 2463–2474
   PubMed Web of Science ®Google Scholar
• Odwyer P. J., Wagner B., Leyland-Jones B., Wittes R. E., Cheson B., And D., Hoth D. F. 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug. Ann. Intern. Med. 1988; 108: 733–743
   PubMed Web of Science ®Google Scholar
• Huang M., Ye Y., Chen S., Chai J., Lu J., Lin Z., Gu L., Wang I. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Castaigne S., Chomienne C., Daniel M. T., Ballerini P., Berger R., Fenaux P., Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Jr., Frankel S. R., Miller W. H., Jr., Scheinberg D. A., Itri L. M., Hittelman W. N., Vyas R., Andreff A., Tafudi A., Jakuobowski A., Gabrilove I., Gordon M., Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N. Engl. J. Med. 1991; 329: 177–189
   Web of Science ®Google Scholar
• Miller W. H., Kakizuka A., Frankel S. R., Warrell R. P., Deblasio A., Levine K., Evans R., And M., Dmitrovsky E. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor-a clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 1992; 89: 2694–2698
   PubMed Web of Science ®Google Scholar
• Comic M., Delva L., Guidez E, Balitrand N., Degos L. Induction of retinoic acid-binding protein in normal in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res. 1992; 52: 3329–3334
   PubMed Web of Science ®Google Scholar
• Wmell R., Jr. Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies, and implications. Blood 1993; 82: 1949–1953
   PubMed Web of Science ®Google Scholar
• Asou N., Adachi K., Tamura A., Kanamaru S., Kageyama S., Hiraoka A., Omoto E., Akiyama H., Tsubaki K., Saito K., Kuriyama K., Oh H., Kitano K., Miyawaki S., Takeyama K., Yamada O., Nishikawa K., Takahashi M., Matsuda S., Ohtake S., Suzushima H., Emi N., Ohno R. Analysis of prognostic factors in new diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J. Clin. Oncol. 1998; 16: 78–85
   PubMed Web of Science ®Google Scholar
• Lanotte M., Martin-Thouvenin V., Najman S., Balerini P., Valensi F., Berger R. NB4, a maturation inducible cell line with t(15:17) marker isolated from human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080–1086
   PubMed Web of Science ®Google Scholar
• Kasukabe T., Honma Y., Hozumi M., Suda T., Nishii Y. Control of proliferating potential of myeloid leukemia cells during long-term treatment with vitamin D3 analogues and other differentiation inducers in combination with antileukemic drugs: In vitro and in vivo studies. Cancer Res. 1987; 47: 567–572
   PubMed Web of Science ®Google Scholar
• Hozumi M., Waxman S., G.B Rossi and F. Takaku. Design of combination differentiation therapy. In. The Status of Differentiation Therapy of Cancer, S. Waxman. Raven Press., New York 1991; Vol. 11: 347–353
   Google Scholar
• Chen A., Licht J. D., Wu Y., Hellinger N., Scher W., Waxman S. Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents. Blood 1994; 84: 2122–2129
   PubMed Web of Science ®Google Scholar
• Honma Y., Kasukabe T., Hozumi M. Induction of Iysozyme activity by adenosine 3′:5′cyclic monophos-phate in cultured mouse myeloid leukemia cells. Biochem. Biophys. Res. Commun. 1978; 82: 1246–1250
   PubMed Web of Science ®Google Scholar
• McCachren S. S., Nichols J., Kaufman R., And E., Niedel J. E. Dibutyryl cyclic adenosine monophosphate reduces expression of c-myc during HL-60 differentiation. Blood 1986; 68: 412–416
   PubMed Web of Science ®Google Scholar
• Tortora G., Tagliafem P., Clair T., Colamonici O., Neckers L. M., Robins R., And K., Cho-Chung Y. S. Site-selective CAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic, and acute lympbocytic human leukemia cell lines. Blood 1988; 71: 230–233
   PubMed Web of Science ®Google Scholar
• Linevsky J., Cohen M. B., Hartman K. D., Knode M., And C., Glazer R. I. Effect of neplanocin A on differentiation, nucleic acid methylation, and c-myc mRNA expression in human promyelocytic leukemia cells. Mol. Pharmacol. 1985; 28: 45–50
   PubMed Web of Science ®Google Scholar
• Gieseler F., Meyer P., Schiffmann D., Wilms K. Granulocytic differentiation of HL-60 cells is not regulated by DNA de novo methylation. Blut 1989; 58: 159–163
   PubMedGoogle Scholar